AGE Stock Overview
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
AgeX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.10 |
| 52 Week High | US$35.17 |
| 52 Week Low | US$10.90 |
| Beta | 1.19 |
| 1 Month Change | -14.70% |
| 3 Month Change | -23.49% |
| 1 Year Change | -48.68% |
| 3 Year Change | -80.64% |
| 5 Year Change | -92.39% |
| Change since IPO | -88.35% |
Recent News & Updates
Shareholder Returns
| AGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.6% | -4.2% | -3.7% |
| 1Y | -48.7% | -2.0% | 20.5% |
Return vs Industry: AGE underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: AGE underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| AGE volatility | |
|---|---|
| AGE Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AGE's share price has been volatile over the past 3 months.
Volatility Over Time: AGE's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Joanne Hackett | www.agexinc.com |
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology.
AgeX Therapeutics, Inc. Fundamentals Summary
| AGE fundamental statistics | |
|---|---|
| Market cap | US$31.51m |
| Earnings (TTM) | -US$14.80m |
| Revenue (TTM) | US$142.00k |
195.5x
P/S Ratio-1.9x
P/E RatioIs AGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGE income statement (TTM) | |
|---|---|
| Revenue | US$142.00k |
| Cost of Revenue | US$40.00k |
| Gross Profit | US$102.00k |
| Other Expenses | US$14.91m |
| Earnings | -US$14.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.92 |
| Gross Margin | 71.83% |
| Net Profit Margin | -10,424.65% |
| Debt/Equity Ratio | 81.5% |
How did AGE perform over the long term?
See historical performance and comparison